DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Odanacatib
Odanacatib
We Need Drugs That…
Targeting Cathepsin K for the Treatment of Osteoporosis – Focus
10 Jahre UNIVERSUM INNERE MEDIZIN Liebe
Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis
Amgen and UCB Push Forward with Bone-Building Antibody
Odanacatib: a Possible New Therapeutic Option for the Treatment of Osteoporosis
Odanacatib, a Cathepsin K Inhibitor for the Treatment of Osteoporosis and Other Skeletal Disorders Associated with Excessive Bone Remodeling E Michael Lewiecki
Der Einfluss Der VO (EG) 1901/2006 Auf Den Off-Label Use in Der Neonatologie“
Richard Eastell1, Eric Vittinghoff2, Li-Yung Lui3, Charles E
A Selective Cathepsin K Inhibitor for the Treatment of Osteoporosis
507 Update 8/25/2018
Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of the North American Menopause Society
The Development of Molecular Biology of Osteoporosis
Bisphosphonates: the First 40Years
For Peer Review Only
Potential Role of Odanacatib in the Treatment of Osteoporosis
Odanacatib for Postmenopausal Osteoporosis
A Review on Interventions to Prevent Osteoporosis and Improve Fracture Healing in Osteoporotic Patients
Top View
Drugs Used in the Treatment of Osteoporosis Osteoporosis
Causes, Consequences, and Treatment of Osteoporosis in Men
Denosumab-Induced Immune Hepatitis
The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: a Stable-Label IV/Oral Study in Healthy Post-Menopausal Women
Mesoporous Silica Nanoparticles for the Potential Treatment of Osteoporosis Nanopartículas Mesoporosas De Sílice Para El Tratamiento Potencial De La Osteoporosis
Review Article Safety of the Cathepsin K Inhibitor Odanacatib in Postmenopausal Women with Osteopenia Or Osteoporosis: a Meta-Analysis
Metastatic Bone Disease: Pathogenesis and Therapeutic Options: Up-Date on Bone Metastasis Management
FDA Indications for Osteoporosis
Study Protocol
Potential First-In-Class Osteoporosis Drug Speeds Through Trials
Bisphosphonate-Associated Osteonecrosis of the Jaw
Osteoporosis Posters and Abstracts from Atlanta CME Activity
Merck & Co. Drops Osteoporosis Drug Odanacatib
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
New Insights Into Treatment of Osteoporosis in Postmenopausal Women
THE GROWING GAP in OSTEOPOROSIS TREATMENT Sundeep Khosla, M.D
Disclosure and Conflicts of Interest Prescription Medicines
Evidence-Based Guidelines for the Pharmacological Treatment of Postmenopausal Osteoporosis: a Consensus Document by the Belgian Bone Club
Potential Role of Odanacatib in the Treatment of Osteoporosis
Odanacatib for Male Osteoporosis – First and Second Line
马丁代尔药物大典38th 01__2027.Pdf